Neurogene Inc. Common Stock (NGNE)
Stock · NASDAQ · Health Care
$36.58as of 8/28/2026
Price chart
Open in TradingViewActive signals
No technical signal is currently active for this symbol.
Support level
$26.23
Industry
Biotechnology: Pharmaceutical Preparations
Fundamentals
- Market cap
- $628.34M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- —
- Dividend yield
- —
- Beta
- —
- Avg. volume
- —
How Neurogene Inc. Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Mar 24, 2025 · via SEC EDGAR / Finnhub
Neurogene Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- NGNENeurogene Inc. Common Stock$36.38▼ 3.91%Market cap $628.34MP/E —
- BBOTBridgeBio Oncology Therapeutics Inc. Common Stock$8.74▼ 4.79%Market cap $660.88MP/E —$7$14.87
- CRMDCorMedix Inc. Common Stock$8.31▼ 0.06%Market cap $592.31MP/E 3.53$6.13$14.96
- CLYMClimb Bio Inc. Common Stock$14.56▼ 3.32%Market cap $676.28MP/E —$1.54$18.33
- MPLTMapLight Therapeutics Inc. Common Stock$12.64▲ 0.80%Market cap $569.09MP/E —$9.1$40.43
- OCSOculis Holding AG Ordinary shares$12.21▼ 1.77%Market cap $689.43MP/E —$10.52$34.48
- CTMXCytomX Therapeutics Inc. Common Stock$3.22▼ 5.99%Market cap $690.12MP/E —$1.9$8.21
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NGNE Neurogene Inc. Common Stock | $628.34M | — | $36.38 | ▼ 3.91% | |
| BBOT BridgeBio Oncology Therapeutics Inc. Common Stock | $660.88M | — | $8.74 | ▼ 4.79% | $7$14.87 |
| CRMD CorMedix Inc. Common Stock | $592.31M | 3.53 | $8.31 | ▼ 0.06% | $6.13$14.96 |
| CLYM Climb Bio Inc. Common Stock | $676.28M | — | $14.56 | ▼ 3.32% | $1.54$18.33 |
| MPLT MapLight Therapeutics Inc. Common Stock | $569.09M | — | $12.64 | ▲ 0.80% | $9.1$40.43 |
| OCS Oculis Holding AG Ordinary shares | $689.43M | — | $12.21 | ▼ 1.77% | $10.52$34.48 |
| CTMX CytomX Therapeutics Inc. Common Stock | $690.12M | — | $3.22 | ▼ 5.99% | $1.9$8.21 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Canaccord Genuity Maintains Buy on Neurogene, Lowers Price Target to $166Benzinga · 8/12/2026
- Guggenheim Maintains Buy on Neurogene, Raises Price Target to $81Benzinga · 8/12/2026
- HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $65Benzinga · 8/12/2026
- Neurogene Q2 EPS $(1.53) Misses $(1.39) EstimateBenzinga · 8/11/2026
Insider Activity
Insider Actions →Acquired
120.0K
Disposed
29.6K
- Cvijic Christine Mikail · July 7, 2026 · Sale4.2K @ $36.13
- Cvijic Christine Mikail · July 6, 2026 · Sale600 @ $36.02
- Cvijic Christine Mikail · July 2, 2026 · Sale1.5K @ $35.23
- Cvijic Christine Mikail · July 2, 2026 · Sale2.5K @ $34.58
- Cvijic Christine Mikail · July 1, 2026 · Sale739 @ $34.06
- Cvijic Christine Mikail · May 6, 2026 · Sale4.8K @ $30.07
- Shafer Christina · May 5, 2026 · Grant120.0K
- Cvijic Christine Mikail · March 26, 2026 · Sale2.6K @ $21.62
- Jordan Julie · March 26, 2026 · Sale828 @ $21.89
- McMinn Rachel · March 26, 2026 · Sale3.4K @ $22.07
- Cobb Stuart · March 13, 2026 · Sale148 @ $22.08
- Cobb Stuart · March 13, 2026 · Sale2.7K @ $21.34
- Cobb Stuart · March 13, 2026 · Sale4.0K @ $20.41
- Cvijic Christine Mikail · March 13, 2026 · Sale263 @ $22.02
- Cvijic Christine Mikail · March 13, 2026 · Sale1.4K @ $21.25
Institutional Ownership
March 31, 2026
- Total shares held
- 16.97M
- Total value held
- $342.01M
- Institutional holders
- 94
Top holders this quarter
- Unknown1.72M
- Unknown1.46M
- Unknown1.42M
- Unknown1.36M
- Unknown1.27M
- Unknown1.01M
- Unknown991.7K
- Unknown782.8K
- Unknown718.4K
- Unknown681.3K
See the full, filterable feed with live charts on the MarketWall dashboard.